In a milestone for modern medicine, the world’s first clinical trial to transplant gene-edited pig kidneys into humans has begun at NYU Langone Health. The procedure, conducted under the direction of Dr. Robert Montgomery, represents a turning point in xenotransplantation—the science of using animal organs to save human lives. The trial, sponsored by United Therapeutics, aims to determine whether genetically engineered pig kidneys can function safely and effectively in people with end-stage renal disease.
Addressing the Organ Shortage Crisis
More than 100,000 Americans are waiting for an organ transplant, and most of them need kidneys. Thousands die each year before a donor can be found. United Therapeutics’ chief of xenotransplantation, Dr. Leigh Peterson, described the effort as “a watershed moment” that could one day eliminate that tragic shortage. The new kidneys, known as UKidneys, have been engineered with ten genetic modifications—six human genes have been added to improve compatibility, while four pig genes that trigger rejection and uncontrolled growth have been removed.
The Science Behind the UKidney
These pigs are bred specifically for medical purposes and are far different from ordinary livestock. Scientists carefully alter their DNA so that their organs more closely resemble human tissue. The resulting kidneys are less likely to trigger immune attacks or grow excessively once implanted. Each transplant patient in the study will be carefully monitored for 24 weeks, checking survival rates, kidney performance, and any signs of infection or rejection. The participants will then be followed for life.
The FDA’s approval for the study follows several “compassionate use” cases, where doctors performed experimental surgeries on critically ill patients. Results were mixed but encouraging. One Alabama woman lived 130 days with a pig kidney before returning to dialysis, and a New Hampshire man survived 271 days before his organ began to fail. Both were remarkable achievements compared to earlier attempts. Dr. Montgomery emphasized that the ability to return to dialysis offers a safety net while researchers continue refining the procedure.
Despite the promise, xenotransplantation carries serious risks. The human immune system can still reject the foreign organ, and there are concerns about possible infections crossing from animals to humans. Patients in the study must meet strict criteria: they must be between 55 and 70 years old, have been on dialysis for at least six months, and have no severe comorbidities or other organ failures. Each recipient will undergo genetic compatibility testing to ensure the highest possible chance of success.
If early results are positive, the study could expand from six participants to as many as fifty across multiple medical centers. United Therapeutics ultimately plans to seek FDA approval for the UKidney as a standard medical treatment. Dr. Montgomery, who has spent decades pushing the boundaries of organ transplantation, called this “a transformative moment in transplant medicine.” He added, “This offers new hope to the thousands of Americans who might otherwise die waiting for a human donor.”
Beyond Kidneys: What’s Next
While kidneys are the immediate focus, scientists believe the same genetic techniques could eventually make other pig organs viable for human use, including hearts, livers, and lungs. Earlier at NYU, researchers successfully tested pig hearts in brain-dead patients, demonstrating that genetically modified organs can function in human bodies for extended periods.
For the first time, researchers are systematically studying whether these organs can become a lasting solution, not just an emergency measure. The NYU team and United Therapeutics call the trial EXPAND—an appropriate name for what may be the beginning of a new era in medicine. If successful, gene-edited pig organs could end the chronic shortage that has claimed so many lives and give hope to the thousands still waiting for a second chance.
